(16797697), S. L., (16797700), S. D. P., (16797703), L. E. O., (16375918), E. G., (16797706), J. P. B., (15135437), D. W., . . . (14940894), T. J. P. (2025). Supplementary Table S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression.
Цитирование в стиле Чикаго (17-е изд.)(16797697), Stephanie Lheureux, et al. Supplementary Table S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression. 2025.
Цитирование MLA (9-е изд.)(16797697), Stephanie Lheureux, et al. Supplementary Table S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression. 2025.